StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Pradip Hotchandani, Prudent Corporate Advisory Services

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byPradip Hotchandani, Prudent Corporate Advisory ServicesHorizon: NA (inferred Swing (≤2wk))11 Aug 2026via CNBC Awaaz.

Entry₹1,134.5Inferred
Target₹1,220
Total upside +7.54% (call closed)
Stop loss₹1,114-1.81% risk
Exit₹1,11419 Aug 2026, 11:00 am
Stop-loss hit-1.81%
Follow Pradip Hotchandani for new calls(20% target hit, 41 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 24 Aug 2026
14 supporting6 neutral3 opposing
Supports the BUY call (14)

Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection

NewsNdtv-Profit·21 Aug · 2d ago

(opens in new tab)

Zydus Lifesciences gets USFDA approval for generic Ascorbic Acid Injection

NewsCnbc-Tv18·21 Aug · 3d ago

(opens in new tab)

Zydus Lifesciences Ltd received final approval from the USFDA for Ascorbic Acid Injection, including 180-days CGT exclusivity.

BSE · Company Update·21 Aug · 3d ago

(opens in new tab)

Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic

NSE · Press Release·11 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (6)

From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, Outlook

NewsNdtv-Profit·12 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.

NSE · Press Release·11 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)

Unaudited financial results for the quarter ended on June 30, 2026

BSE · Board Meeting·11 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price

NewsNdtv-Profit·11 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (3)

Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target

NewsEt-Markets·12 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore

NewsEt-Markets·11 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences received an order from the Superintendent of Stamps, Gandhinagar, demanding recovery of ₹53.47 million in deficient stamp duty and ₹55.07 million in penalties, totaling ₹108.54 mill

BSE · Company Update·29 Jul · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Pradip Hotchandani, Prudent Corporate Advisory Services

Every call and its outcome